Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 27;9(6):349-358.
doi: 10.9740/mhc.2019.11.349. eCollection 2019 Nov.

Multiple sclerosis

Shilpa Klocke, Nicole Hahn

Multiple sclerosis

Shilpa Klocke et al. Ment Health Clin. .

Abstract

Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis. Disease-modifying therapies are now being classified into categories based on level of efficacy. Strategies to use disease-modifying therapies earlier and in a more customizable manner are also emerging. A clinical case study will be used throughout this pearl to review the disease-modifying therapies and use patient-specific factors to develop and provide recommendations on therapeutic strategies for individuals with relapsing forms of multiple sclerosis.

Keywords: disease-modifying therapies; escalation versus induction; guidelines; highly effective; modestly effective; multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

Disclosures: S.K. is a consultant and serves as a part-time Clinical Specialist-Neurology with Wolters Kluwer Health. N.H. has nothing personal to disclose. Psychopharmacology Pearls are review articles intended to highlight both the evidence base available and/or controversial areas of clinical care for psychiatric and neurologic conditions as well as strategies of clinical decision-making used by expert clinicians. As pearls, articles reflect the views and practice of each author as substantiated with evidence-based facts as well as opinion and experience. Articles are edited by members of the Psychopharmacology Pearls Editorial Board as well as peer reviewed by MHC reviewers. This article was developed as part of the 2019 Psychopharmacology Pearls product for BCPP recertification credit. The course information and testing center is at https://cpnp.org/379404.

References

    1. Costello K, Halper J, Kalb R, Skutnik L, Rapp R. [Internet]. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A consensus paper by the Multiple Sclerosis Coalition. 2019 Jun; [updated. cited 2019 Sep 14]. Available from: http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles....
    1. Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27–40. DOI: 10.1111/ene.13819 PubMed PMID: 30300457. - DOI - PubMed
    1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169–80. DOI: 10.1056/NEJMra1401483 PubMed PMID: 29320652. - DOI - PMC - PubMed
    1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–36. DOI: 10.1016/S0140-6736(18)30481-1 PubMed PMID: 29576504. - DOI - PubMed
    1. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029–40. DOI: 10.1212/WNL.0000000000007035 PubMed PMID: 30770430. - DOI - PMC - PubMed

LinkOut - more resources